Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

FDA’s year-end approvals take annual tally to 46

The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’cabozantinib franchise to $1bn in sales in 2025.
Ipsen’s liver cancer treatment clears phase III trial

Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial
Pfizer's SMO inhibitor boosts survival in blood cancer trial

Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is
Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Ipsen and Exelixis will use the findings to pursue new first-line indications in RCC, a prevalent and difficult to diagnose cancer. ... therapy. French biotech Ipsen signed and exclusive licensing agreement with Exelixis in February for the
HIV prevention pill heads July CHMP recommendations

Originally developed by Exelixis, cabozantinib was licensed by Ipsen in a $855m deal announced in February.

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Accelerating innovation

Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... It currently has a second-line licence in Europe, but Ipsen
Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Medical Writer - (London, Brighton or Copenhagen): Competitive

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Manager – Med Comms – London: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Senior Medical Writer: Great salary and benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Programme Executive: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Director – Medical Education – Oxford: Negotiable

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...